SG11201408152VA - Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency - Google Patents
Hgh-xten fusion protein and its use in the treatment of growth hormone deficiencyInfo
- Publication number
- SG11201408152VA SG11201408152VA SG11201408152VA SG11201408152VA SG11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA SG 11201408152V A SG11201408152V A SG 11201408152VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- hgh
- fusion protein
- growth hormone
- xten
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 206010056438 Growth hormone deficiency Diseases 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 101000642591 Xenopus laevis Somatotropin-A Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 238000011285 therapeutic regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261689390P | 2012-06-05 | 2012-06-05 | |
| US201261663475P | 2012-06-22 | 2012-06-22 | |
| US201361763753P | 2013-02-12 | 2013-02-12 | |
| PCT/US2013/031673 WO2013184216A1 (en) | 2012-06-05 | 2013-03-14 | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201408152VA true SG11201408152VA (en) | 2015-01-29 |
Family
ID=47998551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201408152VA SG11201408152VA (en) | 2012-06-05 | 2013-03-14 | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency |
Country Status (17)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CN108530543B (zh) | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| HK1216617A1 (zh) * | 2013-03-11 | 2016-11-25 | Amunix Operating Inc. | 用人生长激素类似物治疗小儿生长激素缺乏症 |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017136583A1 (en) | 2016-02-02 | 2017-08-10 | Versartis, Inc. | Growth hormone treatment adherence system |
| WO2017142331A1 (en) * | 2016-02-17 | 2017-08-24 | Genexine, Inc. | Pharmaceutical composition comprising recombinant hgh for the treatment of growth hormone deficiency |
| CN109152816B (zh) | 2016-02-17 | 2022-08-16 | 株式会社吉耐森 | 用于治疗生长激素缺乏症的包含重组hgh的药物组合物 |
| EP3491012A4 (en) * | 2016-07-27 | 2020-07-01 | Amunix Operating Inc. | TREATING ADULT GROWTH HORMONE WITH ANALOGUE OF HUMAN GROWTH HORMONE |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| SG11202005674XA (en) | 2017-12-21 | 2020-07-29 | Amunix Pharmaceuticals Inc | Release segments and binding compositions comprising same |
| MX2021002279A (es) | 2018-08-27 | 2021-05-27 | Regeneron Pharma | Uso de espectroscopia raman en la purificacion corriente abajo. |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | FUSION PROTEINS FROM GLP-1 AND GDF15 AND CONJUGATES THEREOF |
| CN115322794A (zh) | 2020-01-11 | 2022-11-11 | 北京质肽生物医药科技有限公司 | Glp-1和fgf21的融合蛋白的缀合物 |
| JP2023545684A (ja) | 2020-09-30 | 2023-10-31 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートおよび使用の方法 |
| CN116554343B (zh) * | 2022-01-30 | 2024-07-12 | 领诺(上海)医药科技有限公司 | 一种长效重组人生长激素及其应用 |
| JP2025512832A (ja) | 2022-03-30 | 2025-04-22 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法 |
| CN116003632A (zh) * | 2022-12-07 | 2023-04-25 | 北京大学 | 长效缓释型人重组生长激素融合蛋白及其药物组合物和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898830A (en) | 1979-07-05 | 1990-02-06 | Genentech, Inc. | Human growth hormone DNA |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| US6406632B1 (en) | 1998-04-03 | 2002-06-18 | Symyx Technologies, Inc. | Rapid characterization of polymers |
| GB9815157D0 (en) | 1998-07-13 | 1998-09-09 | Metron Designs Ltd | High resolution pulse width setting from relatively low frequency clocks |
| US20030228309A1 (en) | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7294513B2 (en) | 2002-07-24 | 2007-11-13 | Wyatt Technology Corporation | Method and apparatus for characterizing solutions of small particles |
| US8703717B2 (en) * | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8680050B2 (en) * | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| CN108530543B (zh) * | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| NO2440241T3 (enrdf_load_stackoverflow) * | 2009-06-08 | 2018-01-06 |
-
2013
- 2013-03-14 KR KR20147036167A patent/KR20150021072A/ko not_active Withdrawn
- 2013-03-14 BR BR112014030404A patent/BR112014030404A2/pt not_active IP Right Cessation
- 2013-03-14 SG SG11201408152VA patent/SG11201408152VA/en unknown
- 2013-03-14 WO PCT/US2013/031673 patent/WO2013184216A1/en active Application Filing
- 2013-03-14 HK HK15109368.8A patent/HK1208629A1/xx unknown
- 2013-03-14 ES ES13712656T patent/ES2733220T3/es active Active
- 2013-03-14 JP JP2015516010A patent/JP2015520188A/ja active Pending
- 2013-03-14 NZ NZ702557A patent/NZ702557A/en not_active IP Right Cessation
- 2013-03-14 CN CN201710596161.5A patent/CN107320719A/zh not_active Withdrawn
- 2013-03-14 US US13/829,369 patent/US20140162949A1/en not_active Abandoned
- 2013-03-14 CA CA2875827A patent/CA2875827A1/en not_active Abandoned
- 2013-03-14 DK DK13712656.1T patent/DK2858664T3/da active
- 2013-03-14 CN CN201380041556.9A patent/CN104519903A/zh active Pending
- 2013-03-14 AU AU2013272220A patent/AU2013272220A1/en not_active Abandoned
- 2013-03-14 MX MX2014014927A patent/MX2014014927A/es unknown
- 2013-03-14 EP EP13712656.1A patent/EP2858664B1/en active Active
-
2014
- 2014-12-04 IL IL236070A patent/IL236070A0/en unknown
- 2014-12-05 PH PH12014502738A patent/PH12014502738A1/en unknown
-
2017
- 2017-03-08 JP JP2017043512A patent/JP2017125051A/ja active Pending
- 2017-07-13 US US15/648,967 patent/US20180051063A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140162949A1 (en) | 2014-06-12 |
| WO2013184216A1 (en) | 2013-12-12 |
| US20180051063A1 (en) | 2018-02-22 |
| PH12014502738A1 (en) | 2015-02-02 |
| EP2858664A1 (en) | 2015-04-15 |
| ES2733220T3 (es) | 2019-11-28 |
| CN107320719A (zh) | 2017-11-07 |
| HK1208629A1 (en) | 2016-03-11 |
| JP2017125051A (ja) | 2017-07-20 |
| MX2014014927A (es) | 2015-05-15 |
| DK2858664T3 (da) | 2019-07-08 |
| IL236070A0 (en) | 2015-01-29 |
| BR112014030404A2 (pt) | 2017-06-27 |
| EP2858664B1 (en) | 2019-05-08 |
| JP2015520188A (ja) | 2015-07-16 |
| AU2013272220A1 (en) | 2015-01-15 |
| CN104519903A (zh) | 2015-04-15 |
| NZ702557A (en) | 2017-06-30 |
| CA2875827A1 (en) | 2013-12-12 |
| KR20150021072A (ko) | 2015-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201408152VA (en) | Hgh-xten fusion protein and its use in the treatment of growth hormone deficiency | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201903021WA (en) | Anti-human 4-1 bb antibodies and use thereof | |
| SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201407548UA (en) | Treatment of amd using aav sflt-1 | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201807538PA (en) | Crispr-cpf1-related methods, compositions and components for cancer immunotherapy | |
| SG11201807401RA (en) | Therapeutic membrane vesicles | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
| SG11201806322QA (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| SG11201900138TA (en) | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof | |
| SG11201407340YA (en) | Treatment of myelosuppression | |
| SG11201406625XA (en) | Anti-fcrn antibodies | |
| SG11201408347UA (en) | Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides | |
| SG11201407512VA (en) | High-concentration monoclonal antibody formulations | |
| SG11201407205WA (en) | System and process for retina phototherapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function |